Misryoum examines what psychedelic therapy research shows, how “set and setting” may matter, and what a new policy push could change.
A sudden policy push is putting psychedelics back at the center of the national debate, but the real story still hinges on what careful clinical research can—and cannot—prove.
In recent days. an executive order signed by President Trump has been framed as a way to accelerate access to psychedelic-based therapies.. Misryoum reports that this has renewed attention for the idea of psychedelic therapy using drugs such as psilocybin and MDMA. which have drawn serious scientific interest for conditions including depression. anxiety. PTSD. and substance-use disorders.. After years in which psychedelic research largely stalled. the field has restarted with formal approvals and a growing pipeline of studies.
That resurgence is closely tied to how these treatments are delivered.. A recurring theme in conversations with experts is that outcomes may depend not only on the drug. but also on the psychological and environmental context surrounding the dosing.. Clinicians and researchers often refer to “set and setting. ” a concept that captures how a person’s mindset and the therapeutic setting can shape the experience.. Separating the effects of the medicine from the effects of therapy is proving difficult because many protocols combine both. and there is not yet a single universally accepted way to compare results.
This matters because if therapy scaffolding is a major driver of benefit, then simply making a drug easier to obtain may not deliver the same outcomes that trials are designed to test.
Meanwhile. a parallel trend is emerging: some companies and practitioners are aiming to deliver psychedelics with less intensive oversight. or even modifying molecules to reduce the intensity of the experience.. Supporters argue this could broaden access and potentially lower barriers. but critics emphasize that safety and effectiveness cannot be assumed when protocols change.. Even ketamine—often discussed in the same broad cultural orbit—illustrates the complexity. as off-label and at-home use raise questions about how safely and effectively treatment can be managed outside structured clinical settings.
The science also intersects with the politics of advocacy.. In Misryoum’s reporting. attention has turned to prominent figures within the administration who have expressed personal support for psychedelics and who may help keep momentum high.. At the center of this political momentum is an emphasis on accelerating research and access. even as scientists continue to stress that promising early findings are not the same as established. widely standardized therapies.
One particularly notable example is ibogaine. a psychedelic that has attracted advocates who are especially focused on addiction and veterans’ mental health.. Research into ibogaine is still in early stages. and concerns have been raised about medical risks and the intensity of its effects.. Still. interest has grown partly because people seeking such treatments have often had to travel abroad. and advocates argue that U.S.-based pathways could make investigation and oversight more feasible.
This is important because ibogaine and similar candidates highlight a key gap in the public conversation: broad claims about “healing” may outpace the cautious, condition-specific evidence that regulators and clinicians look for when deciding what should be approved.
For researchers. the near-term impact of policy changes may be less about suddenly changing scientific outcomes and more about shifting the administrative and funding landscape.. Misryoum notes that the executive order includes steps intended to support cooperation with states that run psychedelic-related trials and may speed aspects of regulatory review through existing mechanisms.. If these efforts translate into more studies. the field’s biggest scientific question—how much benefit comes from the drug versus the therapy context—may finally become testable at a larger scale.
In the end, the central promise of psychedelic medicine is not a shortcut to cures, but a chance to build reliable, evidence-based treatments. What matters most now is whether expanded research can turn compelling early signals into therapies that are safe, consistent, and clearly understood.